RxDoctor Payments Data

Harry Acuna, MD

Internal Medicine · Waipahu, HINPI 1598872707

Payments from drug & device makers

$4,246in general payments, 2019–2025

Across 223 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$2K
  • AstraZeneca$1K
  • Amgen$345
  • GSK$120
  • Kowa Pharmaceuticals America, Inc.$119
  • Lilly USA, LLC$96
  • plus $358 from 8 others

What the payments were for

  • Food & beverage$4,240100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,246 in reported general payments places this provider in the 85th percentile of 655 internal medicine providers in Hawaii.

See all internal medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$32,709
Medicare patients
62
Services billed
246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban30$42,885
FarxigaDapagliflozin Propanediol30$42,385
VascepaIcosapent Ethyl43$31,776
JanuviaSitagliptin Phosphate21$31,467
JardianceEmpagliflozin14$22,010
Atorvastatin Calcium610$11,064
SymbicortBudesonide/Formoterol Fumarate29$7,900
Halobetasol Propionate93$5,924
Telmisartan159$5,554
Diclofenac Sodium ErDiclofenac Sodium126$4,176
Rosuvastatin Calcium114$3,886
Lovastatin217$3,817
Colchicine37$3,699
Losartan Potassium284$3,299
Amlodipine Besylate327$3,240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$1,249$50,28559 claims
PfizerEliquis$48$42,88530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 655 internal medicine providers in Hawaii.

Other internal medicine in Waipahu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →